20/20 Biolabs slashes warrant exercise price 80% to $2.25, enabling major dilution

Filed April 28, 2026 · Period ending April 23, 2026 · ~1 min read

Key Changes

• high

  Company cut warrant exercise price from $8.00-$11.42 to $2.25 per share for investor Streeterville, covering 3.6M shares—an 80% discount from February's $11.42 direct listing price, signaling significant stock decline.

  Item 1.01 verify on EDGAR →
• high

  Repricing makes it dramatically cheaper for Streeterville to convert warrants into common stock, potentially diluting existing shareholders by millions of shares at a fraction of the recent listing price.

  Item 1.01 verify on EDGAR →
• medium

  Company retains 90-day right to cancel the repricing with two days' notice, though Streeterville can still exercise warrants at $2.25 during that notice period, limiting the company's ability to prevent dilution.

  Item 1.01 verify on EDGAR →